Filing Details
- Accession Number:
- 0001012975-18-000925
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-07-20 17:19:19
- Reporting Period:
- 2018-07-20
- Accepted Time:
- 2018-07-20 17:19:19
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1658247 | Crinetics Pharmaceuticals Inc. | CRNX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1164426 | Joseph Edelman | 51 Astor Place, 10Th Floor New York NY 10003 | No | No | Yes | No | |
1224962 | Perceptive Advisors Llc | 51 Astor Place, 10Th Floor New York NY 10003 | Yes | No | Yes | No | |
1249675 | Ltd Fund Master Sciences Life Perceptive | 51 Astor Place, 10Th Floor New York NY 10003 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-07-20 | 1,880,305 | $0.00 | 1,880,305 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2018-07-20 | 400,000 | $17.00 | 2,280,305 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B Preferred Stock | Disposition | 2018-07-20 | 6,186,205 | $0.00 | 1,880,305 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect |
Footnotes
- The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
- The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.